Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (1): 47-51.DOI: 10.3969/j.issn.1673-8640.2026.01.008
Previous Articles Next Articles
WANG Bing1, YANG Yuwei2, LIU Junmei1, LI Yanqiu3, PENG Bi1(
)
Received:2024-09-24
Revised:2025-04-01
Online:2026-01-30
Published:2026-01-30
Contact:
PENG Bi
CLC Number:
WANG Bing, YANG Yuwei, LIU Junmei, LI Yanqiu, PENG Bi. Application of reticulocyte hemoglobin content in diagnosing thalassemia in children[J]. Laboratory Medicine, 2026, 41(1): 47-51.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.01.008
| 基因类型 | 例数 | 构成比/% |
|---|---|---|
| α-地贫 | 154 | 100.00 |
| --SEA/αα | 109 | 70.78 |
| -α3.7/αα | 27 | 17.53 |
| -α4.2/αα | 12 | 7.79 |
| αCSα/αα | 3 | 1.95 |
| --SEA/-α4.2 | 3 | 1.95 |
| β-地贫 | 248 | 100.00 |
| CD17/βN | 87 | 35.08 |
| CD41-42/βN | 64 | 25.81 |
| IVS-Ⅱ-654/βN | 55 | 22.18 |
| βEM/βN | 9 | 3.63 |
| CD43/βN | 9 | 3.63 |
| CD27-28/βN | 8 | 3.22 |
| CD71-72/βN | 7 | 2.82 |
| Int/βN | 6 | 2.42 |
| CD41-42/CD71-72 | 3 | 1.21 |
| α-地贫合并β-地贫 | 8 | 100.00 |
| -α3.7/αα;CD17/βN | 4 | 50.00 |
| -α3.7/αα;IVS-Ⅱ-654/βN | 3 | 37.50 |
| -α4.2/αα;CD41-42/βN | 1 | 12.50 |
| 基因类型 | 例数 | 构成比/% |
|---|---|---|
| α-地贫 | 154 | 100.00 |
| --SEA/αα | 109 | 70.78 |
| -α3.7/αα | 27 | 17.53 |
| -α4.2/αα | 12 | 7.79 |
| αCSα/αα | 3 | 1.95 |
| --SEA/-α4.2 | 3 | 1.95 |
| β-地贫 | 248 | 100.00 |
| CD17/βN | 87 | 35.08 |
| CD41-42/βN | 64 | 25.81 |
| IVS-Ⅱ-654/βN | 55 | 22.18 |
| βEM/βN | 9 | 3.63 |
| CD43/βN | 9 | 3.63 |
| CD27-28/βN | 8 | 3.22 |
| CD71-72/βN | 7 | 2.82 |
| Int/βN | 6 | 2.42 |
| CD41-42/CD71-72 | 3 | 1.21 |
| α-地贫合并β-地贫 | 8 | 100.00 |
| -α3.7/αα;CD17/βN | 4 | 50.00 |
| -α3.7/αα;IVS-Ⅱ-654/βN | 3 | 37.50 |
| -α4.2/αα;CD41-42/βN | 1 | 12.50 |
| 指标 | 例数 | RBC计数/(×1012L-1) | Hb/(g·L-1) | MCV/fL | MCH/pg |
|---|---|---|---|---|---|
| TT0组 | 300 | 5.31±0.86 | 107.81±13.81 | 65.35±7.92 | 20.82±3.29 |
| TT1组 | 110 | 5.25±0.60 | 103.38±11.13* | 62.35±5.30* | 19.62±2.04* |
| IDA组 | 90 | 4.82±0.70*# | 89.69±16.13*# | 70.17±6.8*# | 22.74±2.76*# |
| 对照组 | 80 | 4.32±0.44*#∆ | 119.55±6.93*#∆ | 83.09±6.41*#∆ | 28.30±2.66*#∆ |
| F值 | 40.568 | 78.745 | 150.147 | 156.494 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 指标 | MCHC/(g·L-1) | RET%/% | Ret-He/pg | SF/(μg·L-1) | |
| TT0组 | 316.20±17.21 | 1.92±0.75 | 22.46±3.93 | 38.36±19.33 | |
| TT1组 | 309.05±16.22* | 2.02±0.79 | 21.98±3.08 | 7.24±3.07* | |
| IDA组 | 292.72±17.54*# | 1.83±0.74 | 26.33±5.90*# | 8.42±4.65* | |
| 对照组 | 340.94±15.02*#∆ | 1.24±0.40*#∆ | 33.15±2.93*#∆ | 50.56±19.33*#∆ | |
| F值 | 120.628 | 21.087 | 87.714 | 181.424 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 指标 | 例数 | RBC计数/(×1012L-1) | Hb/(g·L-1) | MCV/fL | MCH/pg |
|---|---|---|---|---|---|
| TT0组 | 300 | 5.31±0.86 | 107.81±13.81 | 65.35±7.92 | 20.82±3.29 |
| TT1组 | 110 | 5.25±0.60 | 103.38±11.13* | 62.35±5.30* | 19.62±2.04* |
| IDA组 | 90 | 4.82±0.70*# | 89.69±16.13*# | 70.17±6.8*# | 22.74±2.76*# |
| 对照组 | 80 | 4.32±0.44*#∆ | 119.55±6.93*#∆ | 83.09±6.41*#∆ | 28.30±2.66*#∆ |
| F值 | 40.568 | 78.745 | 150.147 | 156.494 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 指标 | MCHC/(g·L-1) | RET%/% | Ret-He/pg | SF/(μg·L-1) | |
| TT0组 | 316.20±17.21 | 1.92±0.75 | 22.46±3.93 | 38.36±19.33 | |
| TT1组 | 309.05±16.22* | 2.02±0.79 | 21.98±3.08 | 7.24±3.07* | |
| IDA组 | 292.72±17.54*# | 1.83±0.74 | 26.33±5.90*# | 8.42±4.65* | |
| 对照组 | 340.94±15.02*#∆ | 1.24±0.40*#∆ | 33.15±2.93*#∆ | 50.56±19.33*#∆ | |
| F值 | 120.628 | 21.087 | 87.714 | 181.424 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 指标 | 例数 | RBC计数/ (×1012L-1) | Hb/ (g·L-1) | MCV/ fL | MCH/ pg | MCHC/ (g·L-1) | RET%/ % | Ret-He/ pg |
|---|---|---|---|---|---|---|---|---|
| A0组 | 104 | 5.23±0.93 | 111.57±13.34 | 68.25±7.31 | 21.68±2.66 | 314.06±15.44 | 1.90±0.77 | 22.98±3.97 |
| B0组 | 188 | 5.34±0.81 | 105.67±13.67* | 63.25±6.89* | 20.12±3.00* | 307.80±10.18* | 1.92±0.75 | 22.15±3.89 |
| A1组 | 40 | 5.45±0.36 | 107.47±12.26 | 64.05±6.37* | 19.34±2.05* | 300.63±16.44*# | 1.97±0.84 | 21.96±3.66 |
| B1组 | 70 | 5.17±0.65 | 101.38±9.49* | 61.29±4.32* | 19.68±2.00* | 300.52±7.61*# | 2.07±0.76 | 21.93±2.78 |
| F值 | 7.618 | 32.068 | 24.437 | 20.324 | 30.295 | 0.855 | 15.887 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.491 | <0.001 |
| 指标 | 例数 | RBC计数/ (×1012L-1) | Hb/ (g·L-1) | MCV/ fL | MCH/ pg | MCHC/ (g·L-1) | RET%/ % | Ret-He/ pg |
|---|---|---|---|---|---|---|---|---|
| A0组 | 104 | 5.23±0.93 | 111.57±13.34 | 68.25±7.31 | 21.68±2.66 | 314.06±15.44 | 1.90±0.77 | 22.98±3.97 |
| B0组 | 188 | 5.34±0.81 | 105.67±13.67* | 63.25±6.89* | 20.12±3.00* | 307.80±10.18* | 1.92±0.75 | 22.15±3.89 |
| A1组 | 40 | 5.45±0.36 | 107.47±12.26 | 64.05±6.37* | 19.34±2.05* | 300.63±16.44*# | 1.97±0.84 | 21.96±3.66 |
| B1组 | 70 | 5.17±0.65 | 101.38±9.49* | 61.29±4.32* | 19.68±2.00* | 300.52±7.61*# | 2.07±0.76 | 21.93±2.78 |
| F值 | 7.618 | 32.068 | 24.437 | 20.324 | 30.295 | 0.855 | 15.887 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.491 | <0.001 |
| [1] | 刘勇, 林晓英, 黄燕, 等. MCV、MCH、RBC脆性和HbA2在广东地区α-地中海贫血筛查中的价值[J]. 中国实验血液学杂志, 2020, 28(5):1679-1682. |
| [2] |
URRECHAGA E, BORQUE L, ESCANERO J F. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability[J]. Int J Lab Hematol, 2013, 35(2):144-149.
DOI PMID |
| [3] | 袁秋蓉, 牛诗琼, 林雪萍, 等. RBC、Ret-He与HbA2联合检测对地中海贫血的临床价值[J]. 中国实验血液学杂志, 2021, 29(1):203-206. |
| [4] | 彭碧, 马永能, 杨渝伟, 等. 网织红细胞血红蛋白含量对轻型地中海贫血患者妊娠期铁缺乏状态的应用评价[J]. 检验医学, 2020, 35(1):20-24. |
| [5] | 刘佳丽, 王薇, 何法霖, 等. 全国110家妇幼保健院及儿童医院检验科儿童全血细胞计数参考区间调查与分析[J]. 中华检验医学杂志, 2019, 42(4):277-281. |
| [6] | 曹科, 马东礼, 罗小娟, 等. 全自动血细胞分析流水线网织红细胞参数参考区间在儿科实验室适用性验证[J]. 检验医学与临床, 2016, 13(2):184-185. |
| [7] | 《中华儿科杂志》编辑委员会, 中华医学会儿科学分会血液学组,中华医学会儿科学分会儿童保健学组. 儿童缺铁和缺铁性贫血防治建议[J]. 中华儿科杂志, 2008, 46(7):502-504. |
| [8] |
ZHUANG J, JIANG Y, CHEN Y, et al. Third-generation sequencing identified two rare α-chain variants leading to hemoglobin variants in Chinese population[J]. Mol Genet Genomic Med, 2024, 12(1):e2365.
DOI URL |
| [9] |
KADEGASEM P, SONGDEJ D, LERTTHAMMAKIAT S, et al. Reticulocyte hemoglobin equivalent in a thalassemia-prevalent area[J]. Pediatr Int, 2019, 61(3):240-245.
DOI PMID |
| [10] | 欧容, 陈红霞, 余林, 等. 重庆地区地中海贫血患儿的临床分析[J]. 中国实验血液学杂志, 2024, 32(1):214-218. |
| [11] | 唐燕, 李佳熹, 郭远林, 等. 成都市北城地区0-18岁珠蛋白生成障碍性贫血患儿的基因突变类型及频率分析[J]. 检验医学与临床, 2023, 20(14):2122-2124. |
| [12] |
LOU J W, SUN M N, MAO A P, et al. Molecular spectrum and prevalence of thalassemia investigated by third-generation sequencing in the Dongguan region of Guangdong Province,Southern China[J]. Clin Chim Acta, 2023, 551:117622.
DOI URL |
| [13] | 李东明, 黄秀宁, 赵桓, 等. 中国广西崇左地区育龄人群地中海贫血基因突变类型的分析[J]. 中国实验血液学杂志, 2023, 31(6):1804-1810. |
| [14] |
LIAN Y, SHI J, NIE N, et al. Reticulocyte hemoglobin equivalent(Ret-He)combined with red blood cell distribution width has a differentially diagnostic value for thalassemias[J]. Hemoglobin, 2019, 43(4):229-235.
DOI URL |
| [15] | 贾连玲, 欧红玲, 王欢, 等. 网织红细胞新参数对贫血性疾病的诊断价值[J]. 国际检验医学杂志, 2021, 42(13):1563-1566. |
| [16] | 崔丽娟. MCV、RDW、MCH及网织红细胞参数在小儿地中海贫血与缺铁性贫血鉴别诊断中的应用分析[J]. 现代诊断与治疗, 2020, 31(23):3817-3819. |
| [17] | NAKASHIMA M. Utility of Ret-He for determining cause of microcytosis in suspected hemoglobinopathy/thalassemia patients[J]. Int J Lab Hematol, 2016, 38(6):79. |
| [18] |
CHINUDOMWONG P, BINYASING A, TRONGSAKUL R, et al. Diagnostic performance of reticulocyte hemoglobin equivalent in assessing the iron status[J]. J Clin Lab Anal, 2020, 34(6):e23225.
DOI URL |
| [19] |
KADEGASEM P, SONGDEJ D, LERTTHAMMAKIAT S, et al. Reticulocyte hemoglobin equivalent in a thalassemia-prevalent area[J]. Pediatr Int, 2019, 61(3):240-245.
DOI PMID |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||